Segall Bryant & Hamill LLC Sells 93,431 Shares of Galapagos NV (NASDAQ:GLPG)

Segall Bryant & Hamill LLC lowered its position in shares of Galapagos NV (NASDAQ:GLPG - Free Report) by 11.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 705,648 shares of the biotechnology company's stock after selling 93,431 shares during the period. Segall Bryant & Hamill LLC owned 1.07% of Galapagos worth $20,316,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Creative Planning acquired a new stake in shares of Galapagos in the second quarter valued at approximately $456,000. Signaturefd LLC raised its holdings in Galapagos by 65.6% in the 3rd quarter. Signaturefd LLC now owns 6,413 shares of the biotechnology company's stock valued at $185,000 after acquiring an additional 2,541 shares in the last quarter. Crossmark Global Holdings Inc. bought a new stake in shares of Galapagos during the 3rd quarter valued at $1,077,000. Headlands Technologies LLC grew its holdings in shares of Galapagos by 56.7% during the 2nd quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company's stock worth $31,000 after purchasing an additional 446 shares in the last quarter. Finally, Stonepine Capital Management LLC increased its position in shares of Galapagos by 23.2% in the second quarter. Stonepine Capital Management LLC now owns 485,000 shares of the biotechnology company's stock worth $12,018,000 after purchasing an additional 91,366 shares during the period. 32.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on GLPG shares. Kepler Capital Markets cut shares of Galapagos from a "hold" rating to a "reduce" rating in a research report on Wednesday. Raymond James downgraded shares of Galapagos from an "outperform" rating to a "market perform" rating in a research report on Friday, August 2nd. Leerink Partnrs raised Galapagos to a "hold" rating in a report on Monday, September 9th. Royal Bank of Canada lowered their price target on Galapagos from $32.00 to $30.00 and set a "sector perform" rating for the company in a report on Friday, November 1st. Finally, Leerink Partners started coverage on Galapagos in a research note on Monday, September 9th. They issued a "market perform" rating and a $24.00 price objective on the stock. Two research analysts have rated the stock with a sell rating and six have assigned a hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $30.75.

Galapagos Trading Down 3.9 %

Galapagos stock opened at $25.64 on Thursday. The stock has a 50-day moving average price of $28.76 and a two-hundred day moving average price of $27.54. Galapagos NV has a 12 month low of $24.16 and a 12 month high of $42.46.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.